Radcliffe Cardiology Announces New Educational Hub, Arrhythmia Academy

Radcliffe Cardiology: An exciting new digital platform – ‘Arrhythmia Academy’ launches today – dedicated to arrhythmia and electrophysiology specialists.

This new scientific content hub is led by Editor-in-Chief Prof Angelo Auricchio, MD, Ph.D., (Lugano, Switzerland) and is supported by a stellar, international editorial board.

In association with leading Cardiovascular content provider Radcliffe Cardiology, Arrhythmia Academy aims to provide high-quality, peer-to-peer content for clinicians interested in cardiac arrhythmias and clinical cardiac care electrophysiology. It will welcome contributions by health care professionals working in this specialty.

Features include:

  • Case Lab: with real-world content, including practical ‘how-to guides’, videos, technical tips and tricks and a host of challenging and unusual case examples designed to enhance study
  • Education: dedicated to key scientific learnings, methods and commentaries
  • Innovations: showcasing new technological developments in AF and EP medicine. Featuring news, conference highlights, late-breaking trials and the latest developments from the industry.
  • Editorial Area: regularly updated with key editorials and opinion pieces on a particular issue, event, or gap in the literature.

VISIT SITE >

All of the content will be created in an accessible and digestible format: short written summaries, presentations, videos, audio podcasts and imagery, aiming to bring clinicians the most relevant and practical information as succinctly and as timely as possible.

If you think you might have something of interest to contribute, you can visit the site now and submit your content.

“As a scientist first, then, as Editor-in-Chief, I am very excited to launch this web-based platform that completes, and significantly expands upon the current editorial offering, with open-access and visual digital content. I am also very grateful to a large number of scientists and key opinion leaders in the field of cardiac arrhythmias, who have accepted to be part of the editorial board and are committed to providing tremendous support to this initiative.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version